Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23368590 | 0.88 | MEN1 (0.58) | MEN1USP2GAAKMT2AKEAP1 | |
| SCHEMBL23368566 | 0.85 | AOC3 (0.51) | MEN1USP2GAAKMT2AKEAP1 | |
| SCHEMBL23368586 | 0.81 | GAA (0.54) | MEN1USP2GAAKMT2AKEAP1 | |
| SCHEMBL24871430 | 0.79 | MEN1 (0.51) | MEN1USP2GAAKMT2AKEAP1 | |
| SCHEMBL23379677 | 0.79 | NAAA (0.49) | MEN1USP2GAAKMT2AKEAP1 | |
| SCHEMBL23368563 | 0.75 | GAA (0.67) | MEN1USP2GAAKMT2AKEAP1 | |
| SCHEMBL5632543 | 0.75 | CHKA (0.46) | MEN1USP2GAAKMT2APDE3B | |
| SCHEMBL975022 | 0.74 | FFAR4 (0.39) | EPHX2CYP11B2PDE3BPDE3APDE10A | |
| Hydrochloric Acid SCHEMBL7954922 | 0.74 | CHKA (0.44) | MEN1USP2GAAKMT2AACACB | |
| SCHEMBL12526590 | 0.73 | AOC3 (0.52) | EPHX2CYP2C9CYP2J2AOC3ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | MEN1 241/4885USP2 4831/4885GAA 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.